Which has stronger earnings & valuation, ORKA or CRVS?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is ORKA or CRVS more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% Corvus Pharmaceuticals N/A -38.92% -35.75%

Which has stronger valuation and earnings, MANE or CRVS?

Veradermics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A -$1.32 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is MANE or CRVS more profitable?

Veradermics' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Corvus Pharmaceuticals N/A -38.92% -35.75%

Corvus Pharmaceuticals (CRVS) Competitors

$15.67 -0.53 (-3.27%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$15.48 -0.19 (-1.18%)

As of 07/10/2026 07:53 PM Eastern

Compare

CRVS vs. DNTH, ORKA, MANE, GRFS, and INDV

Should you buy Corvus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corvus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corvus Pharmaceuticals include Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), Veradermics (MANE), Grifols (GRFS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Dianthus Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Dianthus Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,615.58	-$162.34M	-$4.13	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Dianthus Therapeutics presently has a consensus target price of $117.82, indicating a potential upside of 20.72%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 112.72%. Given Corvus Pharmaceuticals' higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Corvus Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Dianthus Therapeutics' score of 1.08 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Dianthus Therapeutics	Positive
Corvus Pharmaceuticals	Very Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Dianthus Therapeutics beats Corvus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Oruka Therapeutics has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Oruka Therapeutics' return on equity of -26.16% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

In the previous week, Oruka Therapeutics had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Oruka Therapeutics and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Oruka Therapeutics' score of 1.21 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Oruka Therapeutics	Positive
Corvus Pharmaceuticals	Very Positive

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oruka Therapeutics currently has a consensus target price of $134.30, suggesting a potential upside of 54.74%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 112.72%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Oruka Therapeutics beats Corvus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Veradermics?

Veradermics (NYSE:MANE) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Veradermics' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

In the previous week, Veradermics had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Veradermics' score of 0.02 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
Corvus Pharmaceuticals	Very Positive

Veradermics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Veradermics presently has a consensus target price of $135.60, indicating a potential upside of 13.26%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 112.72%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Corvus Pharmaceuticals beats Veradermics on 7 of the 10 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Grifols presently has a consensus price target of $10.00, indicating a potential upside of 37.55%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 112.72%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Grifols has a net margin of 5.54% compared to Corvus Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Grifols has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, Grifols had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Grifols and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Grifols' score of 1.39 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Grifols	Positive
Corvus Pharmaceuticals	Very Positive

Grifols has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	38.26
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Summary

Grifols beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Indivior?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Indivior has a net margin of 19.44% compared to Corvus Pharmaceuticals' net margin of 0.00%. Corvus Pharmaceuticals' return on equity of -38.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Indivior	19.44%	-219.26%	29.40%

In the previous week, Indivior had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Indivior and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Indivior's score of 1.45 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Very Positive
Indivior	Positive

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 112.72%. Indivior has a consensus target price of $40.29, suggesting a potential downside of 0.53%. Given Corvus Pharmaceuticals' higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Indivior has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Indivior	$1.24B	3.99	$210M	$1.95	20.77

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Indivior beats Corvus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.32B	$3.71B	$7.08B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.01%
P/E Ratio	-30.13	21.64	27.42	24.51
Price / Sales	N/A	223.47	502.96	86.34
Price / Cash	123.62	61.98	29.24	49.38
Price / Book	21.47	8.70	10.98	6.43
Net Income	-$15.28M	$23.83M	$3.59B	$331.16M
7 Day Performance	2.89%	-0.75%	-0.26%	0.35%
1 Month Performance	31.35%	8.68%	4.55%	0.57%
1 Year Performance	278.50%	55.85%	29.86%	22.26%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	2.9196 of 5 stars	$15.67 -3.3%	$33.33 +112.7%	+278.5%	$1.32B	N/A	N/A	30
DNTH Dianthus Therapeutics	2.757 of 5 stars	$95.76 +2.6%	$117.82 +23.0%	+386.5%	$5.10B	$2.04M	N/A	80	News Coverage Positive News
ORKA Oruka Therapeutics	3.2969 of 5 stars	$84.50 +1.6%	$134.30 +58.9%	+509.9%	$5.01B	N/A	N/A	N/A	News Coverage Positive News
MANE Veradermics	2.063 of 5 stars	$117.24 -4.0%	$135.60 +15.7%	N/A	$4.90B	N/A	N/A	19	News Coverage Analyst Forecast
GRFS Grifols	4.6592 of 5 stars	$7.21 +0.6%	$10.00 +38.7%	-25.4%	$4.88B	$8.51B	37.95	25,247	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. DNTH, ORKA, MANE, GRFS, and INDV

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Veradermics?

Summary

How does Corvus Pharmaceuticals compare to Grifols?

Summary

How does Corvus Pharmaceuticals compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. DNTH, ORKA, MANE, GRFS, and INDV

How does Corvus Pharmaceuticals compare to Dianthus Therapeutics?

Which has more risk and volatility, DNTH or CRVS?

Which has better valuation and earnings, DNTH or CRVS?

Do analysts recommend DNTH or CRVS?

Is DNTH or CRVS more profitable?

Does the media favor DNTH or CRVS?

Do institutionals and insiders believe in DNTH or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Oruka Therapeutics?

Which has more risk and volatility, ORKA or CRVS?

Which has stronger earnings & valuation, ORKA or CRVS?

Is ORKA or CRVS more profitable?

Does the media favor ORKA or CRVS?

Do institutionals and insiders hold more shares of ORKA or CRVS?

Do analysts prefer ORKA or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Veradermics?

Is MANE or CRVS more profitable?

Does the media favor MANE or CRVS?

Which has stronger valuation and earnings, MANE or CRVS?

Do analysts rate MANE or CRVS?

Do institutionals & insiders have more ownership in MANE or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Grifols?

Do insiders & institutionals have more ownership in GRFS or CRVS?

Do analysts prefer GRFS or CRVS?

Is GRFS or CRVS more profitable?

Which has more volatility & risk, GRFS or CRVS?

Does the media prefer GRFS or CRVS?

Which has stronger earnings and valuation, GRFS or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Indivior?

Is CRVS or INDV more profitable?

Does the media refer more to CRVS or INDV?

Do analysts prefer CRVS or INDV?

Do institutionals and insiders hold more shares of CRVS or INDV?

Which has preferable earnings & valuation, CRVS or INDV?

Which has more risk and volatility, CRVS or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools